CL2021001830A1 - Inhibidores de lta4h para el tratamiento de la hidradenitis supurativa - Google Patents

Inhibidores de lta4h para el tratamiento de la hidradenitis supurativa

Info

Publication number
CL2021001830A1
CL2021001830A1 CL2021001830A CL2021001830A CL2021001830A1 CL 2021001830 A1 CL2021001830 A1 CL 2021001830A1 CL 2021001830 A CL2021001830 A CL 2021001830A CL 2021001830 A CL2021001830 A CL 2021001830A CL 2021001830 A1 CL2021001830 A1 CL 2021001830A1
Authority
CL
Chile
Prior art keywords
treatment
hidradenitis suppurativa
lta4h
lta4h inhibitors
inhibitors
Prior art date
Application number
CL2021001830A
Other languages
English (en)
Inventor
Christian Loesche
Carlos Penno
Till Roehn
Grazyna Wieczorek
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2021001830A1 publication Critical patent/CL2021001830A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente divulgación se relaciona con métodos para el tratamiento de la Hidradenitis Supurativa utilizando un inhibidor de LTA4H. También se divulgan en la presente inhibidores de LTA4H, para el tratamiento de pacientes con Hidradenitis Supurativa, así como también medicamentos, regímenes de dosificación, formulaciones farmacéuticas, combinaciones, formas de dosificación, y kits para utilizar en los usos y métodos divulgados.
CL2021001830A 2019-01-11 2021-07-08 Inhibidores de lta4h para el tratamiento de la hidradenitis supurativa CL2021001830A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19151459 2019-01-11
US201962896923P 2019-09-06 2019-09-06

Publications (1)

Publication Number Publication Date
CL2021001830A1 true CL2021001830A1 (es) 2022-04-01

Family

ID=69177186

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021001830A CL2021001830A1 (es) 2019-01-11 2021-07-08 Inhibidores de lta4h para el tratamiento de la hidradenitis supurativa

Country Status (14)

Country Link
US (1) US20220117949A1 (es)
EP (2) EP3908279B1 (es)
JP (1) JP7222102B2 (es)
KR (1) KR102630669B1 (es)
CN (1) CN113260364A (es)
AU (1) AU2020207638B2 (es)
BR (1) BR112021013377A2 (es)
CA (1) CA3124924A1 (es)
CL (1) CL2021001830A1 (es)
ES (1) ES2998786T3 (es)
IL (1) IL284307A (es)
MX (1) MX2021008303A (es)
TW (1) TWI828839B (es)
WO (1) WO2020144604A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022167913A1 (en) * 2021-02-02 2022-08-11 Pfizer Inc. Dosing regime for treatment of chronic hand eczema
US11932630B2 (en) 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives
JP2025517363A (ja) * 2022-05-17 2025-06-05 ザ ユーエービー リサーチ ファンデーション 炎症性皮膚障害を治療または予防するための方法及び組成物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US20060257481A1 (en) * 2005-04-21 2006-11-16 Decode Genetics Ehf. Sustained release formulation and dosing schedule of leukotriene synthesis inhibitor for human therapy
TW200906396A (en) * 2007-02-14 2009-02-16 Janssen Pharmaceutica Nv LTA4H modulators and uses thereof
WO2009143403A1 (en) * 2008-05-23 2009-11-26 Targacept, Inc. Combination therapy for the management hypertension
EP2734516B1 (en) * 2011-07-19 2015-06-17 Boehringer Ingelheim International GmbH Arylpyrazole ethers as inhibitors of leukotriene a4 hydrolase
ES2864862T3 (es) 2013-03-12 2021-10-14 Celltaxis Llc Métodos de inhibición de la leucotrieno A4 hidrolasa
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
CR20160279A (es) 2013-12-20 2016-08-31 Novartis Ag Derivados de ácido heteroaril butanóico como inhibidores de lta4h
LT3380465T (lt) 2015-11-26 2020-11-10 Novartis Ag Diamino piridino dariniai
JOP20190053A1 (ar) 2016-09-23 2019-03-21 Novartis Ag مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
JP7007374B2 (ja) 2016-09-23 2022-01-24 ノバルティス アーゲー 腱及び／又は靭帯損傷に使用するためのインダゾール化合物
CA3045887A1 (en) * 2016-12-09 2018-06-14 Celtaxsys, Inc. Pendant amines and derivatives as inhibitors of leukotriene a4 hydrolase
AU2017371353B2 (en) * 2016-12-09 2022-02-03 Celltaxis, Llc Monamine and monoamine derivatives as inhibitors of leukotriene A4 hydrolase
US11932630B2 (en) * 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives

Also Published As

Publication number Publication date
WO2020144604A1 (en) 2020-07-16
EP4442315A3 (en) 2024-11-20
TW202042804A (zh) 2020-12-01
JP7222102B2 (ja) 2023-02-14
EP4442315A2 (en) 2024-10-09
MX2021008303A (es) 2021-10-13
BR112021013377A2 (pt) 2021-09-14
JP2022516995A (ja) 2022-03-03
US20220117949A1 (en) 2022-04-21
EP3908279B1 (en) 2024-08-28
AU2020207638A1 (en) 2021-07-15
TWI828839B (zh) 2024-01-11
CA3124924A1 (en) 2020-07-16
AU2020207638B2 (en) 2023-04-13
KR20210113278A (ko) 2021-09-15
IL284307A (en) 2021-08-31
CN113260364A (zh) 2021-08-13
EP3908279A1 (en) 2021-11-17
ES2998786T3 (en) 2025-02-21
KR102630669B1 (ko) 2024-01-30

Similar Documents

Publication Publication Date Title
MX381890B (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
MX2024013963A (es) Un antagonista de il-4r util para el tratamiento o la prevencion del asma
CL2018000706A1 (es) Derivados de pirazolopirimidina como inhibidores btk para el tratamiento del cancer.
MX2019005379A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
PE20191474A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer
MX2016004580A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
ECSP12011834A (es) Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, métodos para su tratamiento y sus usos.
MX375286B (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
MX2016007410A (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 cinasas.
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
MX2019003134A (es) Terapia de combinacion.
MX2016016583A (es) Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas.
CL2021001830A1 (es) Inhibidores de lta4h para el tratamiento de la hidradenitis supurativa
MX2017005255A (es) Derivados de carbazol.
MX2020005518A (es) Mezclas no racemicas y usos de las mismas.
CO2021015793A2 (es) Métodos para tratar o prevenir el asma mediante la administración un antagonista de il-33
CL2019003572A1 (es) Combinaciones de brimonidina de dosis baja y usos de las mismas.
CL2021003034A1 (es) Métodos de tratamiento del síndrome de sjögren utilizando un inhibidor de la tirosina quinasa de bruton
CL2020000270A1 (es) Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf.
MX2017013137A (es) Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas.
CL2021003032A1 (es) Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton
CO2022008817A2 (es) Macrociclos para uso en el tratamiento de enfermedades
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
UY33790A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k e inhibidor de mek.